ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
63.918,47
1,64%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Immunovia Ab (publ) (0G8X)

  7. Immunovia Ab (publ) (0G8X) News

0G8X

Immunovia Ab (publ) (0G8X)

Immunovia Ab (publ)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0G8X
DatumZeitQuelleÜberschriftSymbolFirma
04/01/202416h59PR Newswire (US)Immunovia announces financial calendar for financial year 2024LSE:0G8XImmunovia Ab (publ)
04/01/202416h58PR Newswire (US)Immunovia announces financial calendar for financial year 2024LSE:0G8XImmunovia Ab (publ)
21/11/202311h40PR Newswire (US)Bulletin from the extraordinary general meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
21/11/202311h38PR Newswire (US)Bulletin from the extraordinary general meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
09/11/202309h03PR Newswire (US)Immunovia Publishes Interim Report for January-September 2023LSE:0G8XImmunovia Ab (publ)
09/11/202308h59PR Newswire (US)Immunovia Publishes Interim Report for January-September 2023LSE:0G8XImmunovia Ab (publ)
07/11/202316h14PR Newswire (US)Immunovia successfully completes discovery phase of next-generation test developmentLSE:0G8XImmunovia Ab (publ)
07/11/202316h12PR Newswire (US)Immunovia successfully completes discovery phase of next-generation test developmentLSE:0G8XImmunovia Ab (publ)
02/11/202311h02PR Newswire (US)Invitation to Immunovia's Q3 presentationLSE:0G8XImmunovia Ab (publ)
02/11/202311h00PR Newswire (US)Invitation to Immunovia's Q3 presentationLSE:0G8XImmunovia Ab (publ)
27/10/202309h06PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)LSE:0G8XImmunovia Ab (publ)
27/10/202309h03PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)LSE:0G8XImmunovia Ab (publ)
03/10/202311h01PR Newswire (US)Nomination Committee appointed for Immunovia AB (Publ)LSE:0G8XImmunovia Ab (publ)
03/10/202310h56PR Newswire (US)Nomination Committee appointed for Immunovia AB (Publ)LSE:0G8XImmunovia Ab (publ)
30/08/202312h30PR Newswire (US)Immunovia Publishes Interim Report for January-June 2023LSE:0G8XImmunovia Ab (publ)
30/08/202308h56PR Newswire (US)Immunovia Publishes Interim Report for January-June 2023LSE:0G8XImmunovia Ab (publ)
23/08/202320h08PR Newswire (US)Invitation to Immunovia's Q2 presentationLSE:0G8XImmunovia Ab (publ)
23/08/202320h06PR Newswire (US)Invitation to Immunovia's Q2 presentationLSE:0G8XImmunovia Ab (publ)
19/07/202318h47PR Newswire (US)Immunovia announces updated financial calendarLSE:0G8XImmunovia Ab (publ)
12/07/202309h15PR Newswire (US)Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer DetectionLSE:0G8XImmunovia Ab (publ)
12/07/202309h12PR Newswire (US)Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer DetectionLSE:0G8XImmunovia Ab (publ)
09/06/202310h19PR Newswire (US)Chief Executive Officer, Jeff Borcherding, buys Immunovia sharesLSE:0G8XImmunovia Ab (publ)
09/06/202310h11PR Newswire (US)Chief Executive Officer, Jeff Borcherding, buys Immunovia sharesLSE:0G8XImmunovia Ab (publ)
31/05/202312h16PR Newswire (US)Change in number of shares and votes in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
31/05/202312h13PR Newswire (US)Change in number of shares and votes in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
26/05/202313h43PR Newswire (US)Bulletin from the Annual General Meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
26/05/202313h41PR Newswire (US)Bulletin from the Annual General Meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
23/05/202309h03PR Newswire (US)Immunovia Publishes Interim Report for January-March 2023LSE:0G8XImmunovia Ab (publ)
23/05/202309h00PR Newswire (US)Immunovia Publishes Interim Report for January-March 2023LSE:0G8XImmunovia Ab (publ)
22/05/202318h55PR Newswire (US)Changes to the Nomination Committee's proposal to the Annual General Meeting 2023 in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
 Showing the most relevant articles for your search:LSE:0G8X

Kürzlich von Ihnen besucht

TG
DBK
Deutsche Bank
TG
DTE
Deutsche Telekom
USOTC
RHHBY
Roche (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
GOOGL
Alphabet
TG
ALV
Allianz
NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
TG
NOV
Novo Nordisk
TG
432
Arbor Metals
TG
LHA
Deutsche Lufthansa
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
DBI
SDXP
SDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten